Capricor Gross Profit from 2010 to 2024

CAPR Stock

USD 18.62 0.83 4.67%

Capricor Therapeutics Gross Profit yearly trend continues to be relatively stable with very little volatility. Gross Profit is likely to grow to about 25.3 M this year. Gross Profit is the profit Capricor Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2002-03-31

Previous Quarter

3.6 M

Current Value

4.5 B

Quarterly Volatility

593.9 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Capricor Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Capricor Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 2 M or Other Operating Expenses of 51.7 M, as well as many indicators such as Price To Sales Ratio of 4.94, Dividend Yield of 0.0 or PTB Ratio of 6.08. Capricor financial statements analysis is a perfect complement when working with Capricor Therapeutics Valuation or Volatility modules.

Check out the analysis of Capricor Therapeutics Correlation against competitors.

To learn how to invest in Capricor Stock, please use our How to Invest in Capricor Therapeutics guide.

Latest Capricor Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Capricor Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Capricor Therapeutics minus its cost of goods sold. It is profit before Capricor Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Capricor Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Capricor Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 1.75 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Capricor Gross Profit Regression Statistics

	Arithmetic Mean	2,806,158
	Geometric Mean	1,204,218
	Coefficient Of Variation	347.39
	Mean Deviation	6,156,800
	Median	1,354,500
	Standard Deviation	9,748,221
	Sample Variance	95T
	Range	35.3M
	R-Value	0.48
	Mean Square Error	79T
	R-Squared	0.23
	Significance	0.07
	Slope	1,040,345
	Total Sum of Squares	1330.4T

Capricor Gross Profit History

	2024	25.3 M
	2023	24.1 M
	2022	1.9 M
	2021	-799.0
	2020	-8.1 M
	2019	-4.1 M
	2018	1.7 M

Other Fundumenentals of Capricor Therapeutics

Gross Profit Margin

Capricor Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Accounts Payable	Total Liab	Common Stock	Net Debt	Net Receivables	Total Current Assets	Short Term Debt	Intangible Assets	Net Tangible Assets	Long Term Debt	Short Term Investments	Capital Surpluse	Property Plant Equipment	Accumulated Depreciation	Current Deferred Revenue	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.78	-0.93	0.97	0.83	0.11	-0.59	0.74	1.0	-0.43	-0.13	0.56	0.03	0.78	0.92	0.94	0.68	0.68	-0.48	-0.62	0.63	0.63	-0.18
Total Stockholder Equity	0.78		-0.78	0.64	0.3	0.16	-0.89	0.49	0.79	-0.62	-0.05	0.92	-0.38	0.3	0.87	0.74	0.45	0.23	-0.71	-0.79	0.84	0.82	-0.36
Retained Earnings	-0.93	-0.78		-0.87	-0.72	-0.33	0.52	-0.72	-0.92	0.44	-0.03	-0.58	0.12	-0.76	-0.96	-0.91	-0.68	-0.63	0.58	0.72	-0.51	-0.5	0.3
Accounts Payable	0.97	0.64	-0.87		0.91	0.11	-0.45	0.79	0.96	-0.29	-0.13	0.39	0.19	0.83	0.84	0.91	0.72	0.75	-0.31	-0.46	0.53	0.51	-0.05
Total Liab	0.83	0.3	-0.72	0.91		0.03	-0.11	0.7	0.82	-0.11	-0.16	0.04	0.37	0.92	0.64	0.77	0.63	0.82	-0.1	-0.24	0.22	0.24	0.04
Common Stock	0.11	0.16	-0.33	0.11	0.03		-0.13	0.13	0.11	0.21	0.16	0.14	-0.21	0.1	0.2	0.17	0.18	0.14	-0.1	-0.1	0.1	0.08	0.35
Net Debt	-0.59	-0.89	0.52	-0.45	-0.11	-0.13		-0.17	-0.62	0.47	0.15	-0.93	0.22	-0.04	-0.62	-0.49	-0.16	0.08	0.51	0.59	-0.9	-0.91	0.25
Net Receivables	0.74	0.49	-0.72	0.79	0.7	0.13	-0.17		0.73	-0.26	-0.08	0.13	-0.05	0.67	0.7	0.74	0.95	0.83	-0.28	-0.38	0.34	0.21	0.03
Total Current Assets	1.0	0.79	-0.92	0.96	0.82	0.11	-0.62	0.73		-0.43	-0.13	0.58	0.03	0.76	0.92	0.92	0.66	0.65	-0.47	-0.62	0.65	0.65	-0.19
Short Term Debt	-0.43	-0.62	0.44	-0.29	-0.11	0.21	0.47	-0.26	-0.43		-0.25	-0.58	0.47	-0.24	-0.57	-0.42	-0.23	-0.11	0.83	0.8	-0.28	-0.28	0.39
Intangible Assets	-0.13	-0.05	-0.03	-0.13	-0.16	0.16	0.15	-0.08	-0.13	-0.25		-0.02	-0.06	-0.11	0.0	-0.09	-0.08	-0.22	-0.29	-0.31	-0.34	-0.37	0.03
Net Tangible Assets	0.56	0.92	-0.58	0.39	0.04	0.14	-0.93	0.13	0.58	-0.58	-0.02		-0.4	0.05	0.68	0.55	0.14	-0.09	-0.67	-0.72	0.82	0.83	-0.39
Long Term Debt	0.03	-0.38	0.12	0.19	0.37	-0.21	0.22	-0.05	0.03	0.47	-0.06	-0.4		0.2	-0.25	-0.09	-0.08	-0.04	0.62	0.46	-0.2	-0.2	0.18
Short Term Investments	0.78	0.3	-0.76	0.83	0.92	0.1	-0.04	0.67	0.76	-0.24	-0.11	0.05	0.2		0.68	0.74	0.61	0.83	-0.22	-0.36	0.06	0.09	-0.05
Capital Surpluse	0.92	0.87	-0.96	0.84	0.64	0.2	-0.62	0.7	0.92	-0.57	0.0	0.68	-0.25	0.68		0.92	0.65	0.59	-0.63	-0.76	0.61	0.6	-0.33
Property Plant Equipment	0.94	0.74	-0.91	0.91	0.77	0.17	-0.49	0.74	0.92	-0.42	-0.09	0.55	-0.09	0.74	0.92		0.68	0.71	-0.5	-0.6	0.58	0.57	-0.13
Accumulated Depreciation	0.68	0.45	-0.68	0.72	0.63	0.18	-0.16	0.95	0.66	-0.23	-0.08	0.14	-0.08	0.61	0.65	0.68		0.78	-0.29	-0.34	0.35	0.18	0.08
Current Deferred Revenue	0.68	0.23	-0.63	0.75	0.82	0.14	0.08	0.83	0.65	-0.11	-0.22	-0.09	-0.04	0.83	0.59	0.71	0.78		-0.12	-0.17	0.13	0.11	0.16
Long Term Debt Total	-0.48	-0.71	0.58	-0.31	-0.1	-0.1	0.51	-0.28	-0.47	0.83	-0.29	-0.67	0.62	-0.22	-0.63	-0.5	-0.29	-0.12		0.96	-0.33	-0.33	0.44
Short Long Term Debt	-0.62	-0.79	0.72	-0.46	-0.24	-0.1	0.59	-0.38	-0.62	0.8	-0.31	-0.72	0.46	-0.36	-0.76	-0.6	-0.34	-0.17	0.96		-0.38	-0.38	0.5
Net Invested Capital	0.63	0.84	-0.51	0.53	0.22	0.1	-0.9	0.34	0.65	-0.28	-0.34	0.82	-0.2	0.06	0.61	0.58	0.35	0.13	-0.33	-0.38		0.96	-0.13
Net Working Capital	0.63	0.82	-0.5	0.51	0.24	0.08	-0.91	0.21	0.65	-0.28	-0.37	0.83	-0.2	0.09	0.6	0.57	0.18	0.11	-0.33	-0.38	0.96		-0.17
Capital Stock	-0.18	-0.36	0.3	-0.05	0.04	0.35	0.25	0.03	-0.19	0.39	0.03	-0.39	0.18	-0.05	-0.33	-0.13	0.08	0.16	0.44	0.5	-0.13	-0.17

Click cells to compare fundamentals

About Capricor Therapeutics Financial Statements

Capricor Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Capricor Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Capricor Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Capricor Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	24.1 M	25.3 M
Gross Profit Margin	0.96	1.01

Pair Trading with Capricor Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Capricor Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Capricor Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Capricor Stock

0.87	NKTX	Nkarta Inc	Pair Corr
0.79	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.76	VALN	Valneva SE ADR	Pair Corr
0.76	CYRX	Cryoport	Pair Corr
0.72	MTEM	Molecular Templates	Pair Corr

The ability to find closely correlated positions to Capricor Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Capricor Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Capricor Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Capricor Therapeutics to buy it.

The correlation of Capricor Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Capricor Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Capricor Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Capricor Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Capricor Stock Analysis

When running Capricor Therapeutics' price analysis, check to measure Capricor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Capricor Therapeutics is operating at the current time. Most of Capricor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Capricor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Capricor Therapeutics' price. Additionally, you may evaluate how the addition of Capricor Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC